The Goldman Sachs Group Lowers Zoetis (NYSE:ZTS) Price Target to $196.00

Zoetis (NYSE:ZTS) had its price objective reduced by The Goldman Sachs Group from $223.00 to $196.00 in a report issued on Monday, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other analysts have also issued reports on ZTS. Piper Sandler reiterated an overweight rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays cut their price target on shares of Zoetis from $260.00 to $230.00 and set an overweight rating on the stock in a report on Tuesday, April 23rd. Stifel Nicolaus cut their price target on shares of Zoetis from $195.00 to $180.00 and set a buy rating on the stock in a report on Tuesday, April 30th. Finally, StockNews.com cut shares of Zoetis from a strong-buy rating to a buy rating in a report on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis presently has a consensus rating of Buy and a consensus target price of $211.75.

Zoetis Trading Down 2.1 %

ZTS opened at $164.92 on Monday. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market capitalization of $75.25 billion, a PE ratio of 31.78, a P/E/G ratio of 2.57 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The company’s 50-day moving average is $167.64 and its 200 day moving average is $178.93.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.31 earnings per share. As a group, research analysts predict that Zoetis will post 5.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 2,209 shares of company stock valued at $371,293. Company insiders own 0.16% of the company’s stock.

Institutional Trading of Zoetis

Hedge funds and other institutional investors have recently modified their holdings of the business. Cary Street Partners Investment Advisory LLC raised its position in shares of Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after purchasing an additional 6,457 shares during the period. Peak Financial Advisors LLC bought a new stake in Zoetis during the 4th quarter worth approximately $2,776,000. Ninety One UK Ltd increased its holdings in Zoetis by 13.1% during the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after acquiring an additional 12,537 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in Zoetis by 10.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after acquiring an additional 17,976 shares during the period. Finally, Advisor Partners II LLC increased its holdings in Zoetis by 4.0% during the 3rd quarter. Advisor Partners II LLC now owns 24,068 shares of the company’s stock worth $4,187,000 after acquiring an additional 922 shares during the period. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.